目的 探讨疏血通注射液联合纳洛酮治疗慢性肺心病急性加重期对血浆内皮素（ET-1）的影响。方法 采用回顾性与便利抽样研究方法，病例收治时间为2010年2月—2016年12月，选择在此期间在西安市五环集团职工医院诊治的慢性肺心病急性加重期患者122例，按照治疗方法的区别分为观察组与对照组各61例，对照组给予纳洛酮治疗，2 mg加入0.9% NaCl注射液100 mL中静滴，1次/d。观察组在对照组治疗的基础上给予疏血通注射6 mL加入0.9% NaCl注射液100 mL中静滴，1次/d。两组都治疗观察28 d。比较两组疗效、三尖瓣区最大返流速度（V_max）和肺动脉压（PAPs）及ET-1水平，同时比较两组凝血功能指标。结果 对照组总有效率为86.9%，观察组为98.4%，观察组显著高于对照组（P<0.05）。治疗后两组的V_max值、PAPs值与血浆ET-1含量均显著低于治疗前（P<0.05），且观察组显著低于对照组（P<0.05）。治疗后两组的凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）与凝血酶时间（TT）值都显著高于治疗前（P<0.05），且治疗后观察组显著高于对照组（P<0.05）。结论 疏血通注射液联合纳洛酮治疗慢性肺心病急性加重期能抑制血浆ET-1的表达，改善肺动脉压力，具有抗凝的作用，从而有利于提高治疗疗效。

Objective To investigate the effect of Shuxuetong Injection on plasma endothelin (ET-1) in acute exacerbation of chronic pulmonary heart disease.Methods Used a random draw and retrospective study, From February 2010 to December 2016, 122 cases of acute exacerbation of chronic pulmonary heart disease in our hospital were selected and were ivided into observation group and control group with 61 cases in each group accorded to the different treatment methods, the control group was received naloxone treatment, the observation group was given Shuxuetong Injection therapy based on the control group treatment, all the cases were given reated 28 d.Results The total effective rate of the observation group and the control group was 98.4% and 86.9% respectively, and the observation group was significantly higher than that of the control group (P<0.05). After treatment, the value of V_max and PAPs in the two groups were significantly lower than that before treatment (P<0.05), and the value of V_max and PAPs in the observation group after treatment were significantly lower than that of the control group (P<0.05). The plasma ET-1 content in the observation group and the control group after treatment were significantly lower than that before the treatment (P<0.05), and the observation group were also significantly lower than that of the control group (P<0.05). After treatment, the values of PT, APTT and TT were higher than those before treatment (P<0.05), and the values of PT, APTT and TT in the observation group were also higher than those of the control group after the treatment (P<0.05).Conclusion The Shuxuetong injection can inhibit the expression of plasma ET-1 and improve the pulmonary artery pressure in patients with acute exacerbation of chronic pulmonary heart disease, and it has anticoagulant effect, which is beneficial to improve the therapeutic effect.